TLDR MiNK Therapeutics stock moves after Phase 2 pneumonia trial update. agenT-797 shows early gains in oxygenation and infection control. Data presented at 2026 Military Health System Research Symposium event. Patients treated in Ukraine show no major adverse events reported. Mi...